Private health insurance (PHI) is becoming an increasingly important access channel for pharmaceutical companies. As public funding faces growing pressure and reimbursement constraints increase, manufacturers need to explore alternative pathways to improve patient access to innovative therapies.
Watch our recording as Simon-Kucher experts explore how private health insurance can create new market access opportunities and how pharma companies and insurers can work together to develop sustainable, mutually beneficial models.
Participants learn:
- Why private health insurance matters
- How private insurers think and operate
- Where the most relevant access opportunities exist
- Which strategic questions manufacturers should be asking
